GlassScriptPhysician profile
Basmah Jalil
NPI 1649587635
$9,722.55
in general payments reported to CMS, 2019-2025
34 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $640 · 2020: $1,410 · 2021: $2,025 · 2022: $811 · 2023: $84.87 · 2024: $3,513 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,088 · Food and Beverage: $1,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,087.75 |
| Food and Beverage | $1,749.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $2,114.64 | 2024-2025 | |
| Abbvie INC. | $1,529.13 | 2019-2022 | |
| Modernatx, INC. | $1,433.27 | 2024 | |
| Janssen Research & Development, LLC | $896.75 | 2025 | |
| Ucb, INC. | $702.77 | 2019-2025 | Bimzelx |
| Amgen INC. | $693.72 | 2019-2022 | |
| Lilly USA, LLC | $327.35 | 2019-2023 | Taltz |
| Janssen Biotech, INC. | $312.44 | 2019-2023 | Simponi Aria, Remicade, Simponi |
| Glaxosmithkline, LLC. | $268.41 | 2019-2023 | Benlysta |
| Novartis Pharmaceuticals Corporation | $219.27 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $188.38 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $173.52 | 2020-2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $129.73 | 2020-2022 | |
| Pfizer INC. | $128.70 | 2019-2021 | |
| Sobi, INC | $101.59 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $81.13 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $56.36 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.96 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $49.09 | 2020-2022 | |
| Antares Pharma, INC. | $39.95 | 2020-2021 | |
| Madrigal Pharmaceuticals | $29.17 | 2025 | Rezdiffra |
| Genentech USA, INC. | $27.03 | 2021 | |
| Arbor Pharmaceuticals, INC. | $26.71 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $25.46 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.07 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.04 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.68 | 2022 | |
| Radius Health, INC. | $14.62 | 2019 | |
| Amarin Pharma, INC. | $14.62 | 2021 | |
| Currax Pharmaceuticals LLC | $11.41 | 2021 | |
| Almatica Pharma LLC | $11.39 | 2021 | |
| Horizon Therapeutics Plc | $11.19 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basmah Jalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.